Treatment of SLE with anti-CD19 CAR-T cellsCell therapiesLupus nephritisdoi:10.1038/s41581-022-00651-3Ellen F. CarneyNature Reviews NephrologyNature Publishing Group UKNature Reviews Nephrology
The selection of these materials is of crucial importance with regard to the quality of the final CAR-T cell product. Importance of the quality of starting and raw materials The quality of starting and raw materials is crucial for the development of CAR-T cell products. According to Ph. Eur...
Autologous anti-CD19 CAR T cell administration Given the severity of the patients’ conditions, the refractory courses of disease, and considering the encouraging outcomes for CAR T cells in SLE6 and our previously reported isolated patient with MG,10 we decided to treat both patients with MG/LE...
Interest in biological therapy for cancer has surged due to its precise targeting of cancer cells and minimized impact on surrounding healthy tissues. This
The emerging therapeutic approach of CAR-T cell therapy has sparked great interests, extensive studies in preclinical and clinical trials have revealed encouraging therapeutic efficacy in treating a variety of cancers, particularly in treating B-cell hematologic malignancies with CD19 CAR-T cells [3]....
cells. IASO-782 has the potential to treat a range of autoimmune diseases associated with auto-reactive antibodies. As IASO-782 is a fully human antibody, it has potentially low immunogenicity and is less likely to induce anti-drug antibodies after repeated administration. This provides a ...
Chimeric antigen receptor (CAR)-T cell therapy is a promising new treatment for cancer that involves genetically modifying a patient’s T-cells to rec
CAR T-cell generations Adoptive cell therapies (ACTs) have been used to treat cancer for over 30 years. The rationale that led to the chimeric antigen receptor-modified T (CAR T)-cells was to overcome the HLA restriction, the effective presentation of target epitopes, and the lack of a bro...
Besides, even for current CD19 CAR-T therapy for treating B cell cancers, 50 % of patients had disease progression or relapse due to tumor antigen loss and heterogeneity [11]. With this regard, we conclude the four aspects that need to be considered in designing the next-generation CAR-T...
Treatment of hematological malignancies with CAR T cells is showing impressive clinical responses but also development of severe toxicities. In patients treated with CD19 CAR T cells, cytokine release syndrome, tumor lysis syndrome, and macrophage activation syndrome have been observed [103, 104]. Ele...